The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression

AbstractObjectivesThe expression level of Vascular Endothelial Growth Factor (VEGF) is assumed as a prognostic marker for several tumor types, including colorectal cancer. Therefore, the determination of pre- and post-therapy levels of VEGF appears to have great value in the assessment of tumor prognosis. Enzyme-Linked Immunosorbent Assay (ELISA) is commonly used for the determination of serum or plasma VEGF levels, but the method is costly and time-consuming. In this study, we aimed to describe a rapid and cost-effective analysis method to discriminate VEGF overexpressing colorectal cancer-derived conditioned medium (CM).MethodsAttenuated Total Reflection (ATR)-Fourier Transform Infrared (FTIR) spectroscopy, combined with Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA), was used to differentiate VEGF overexpressing colorectal cancer cell line CM from CM obtained from the corresponding control cells which express and secrete relatively lower amount of VEGF.ResultsSamples belong to VEGF overexpressing colorectal cancer cells were clearly distinguished from the control group with very high PC scores as PC1 + PC2 = 96%. Besides, a 100% accurate distinction between these two groups was achieved by the LDA analysis.ConclusionsATR-FTIR spectroscopy combined with pattern recognition techniques was able to discriminate CM of VEGF overexpressing colorectal cancer cells with high efficiency and accuracy.

Download Full-text

miRNA-27b Targets Vascular Endothelial Growth Factor C to Inhibit Tumor Progression and Angiogenesis in Colorectal Cancer

PLoS ONE ◽

10.1371/journal.pone.0060687 ◽

2013 ◽

Vol 8 (4) ◽

pp. e60687 ◽

Cited By ~ 103

Author(s):

Jun Ye ◽

Xianguo Wu ◽

Dang Wu ◽

Pin Wu ◽

Chao Ni ◽

...

Keyword(s):

Colorectal Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tumor Progression ◽

Vascular Endothelial ◽

Factor C ◽

Endothelial Growth Factor

Download Full-text

The non-canonical role of vascular endothelial growth factor-C axis in cancer progression

Experimental Biology and Medicine ◽

10.1177/1535370215583802 ◽

2015 ◽

Vol 240 (6) ◽

pp. 718-724 ◽

Cited By ~ 16

Author(s):

Chu-An Wang ◽

Shaw-Jenq Tsai

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Cancer Progression ◽

Vascular Endothelial ◽

Factor C ◽

Endothelial Growth Factor

Download Full-text

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

Cancer Growth and Metastasis ◽

10.4137/cgm.s7113 ◽

2011 ◽

Vol 4 ◽

pp. CGM.S7113 ◽

Cited By ~ 2

Author(s):

Ozgur Kemik ◽

Ahu Sarbay Kemik ◽

Aziz Sümer ◽

Sevim Purisa ◽

A. Cumhur Dulger ◽

...

Keyword(s):

Colorectal Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Cancer Patients ◽

Elevated Serum ◽

Stage Ii ◽

Vascular Endothelial ◽

Poor Survival ◽

Colorectal Cancer Patients ◽

Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

Download Full-text

MicroRNAs miR-1 and miR-206 Regulate Monocarboxylate Transporter-4 and Vascular Endothelial Growth Factor Gene Expression in Colorectal Cancer

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2020/v32i1330594 ◽

2020 ◽

pp. 141-152

Author(s):

Anas Khaleel ◽

Rowan AlEjielat ◽

Cristina I. Batarseh ◽

Abdallah Ahmed Elbakkoush ◽

Amneh Tarkhan ◽

...

Keyword(s):

Colorectal Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Target Genes ◽

Monocarboxylate Transporter ◽

Cancer Type ◽

Vascular Endothelial ◽

Web Tool ◽

Endothelial Growth Factor ◽

Monocarboxylate Transporter 4

Background: Colorectal cancer (CRC) is currently the third most common cancer type in males and the second most occurring in females. The role of microRNA (miRNA) in the development of colorectal cancer is not fully elucidated. Therefore, understanding the mechanistic interaction between miRNA and their target oncogenes may hold great importance as a possible target for interventional anticancer therapy. Aims: To identify miRNAs that are part of the regulating pathway of Monocarboxylate Transporter-4 (MCT4) and Vascular Endothelial Growth Factor (VEGF) oncogenes. Study Design: We used publicly available prediction tools (e.g. TargetScan, MicroCosm, PicTar, and DIANA-microT-CDS) to identify the possible miRNA that target the two oncogenes. Methodology: We used the GeneMania database to visualize the network and verify gene names and remove ambiguity and duplications. Furthermore, we used miRTarBase database to identify experimentally validated targets which we used to further confirm miRNA-oncogene relationships. Finally, we utilized miR-Mfold web-tool to further visualize the circular structures and the simulated miR-1 and miR-206 targeting arrangements. Results: We found two putative miRNA (miR-1 and miR-206) that may downregulate MCT4 coded by SLC16A3 gene and VEGF which is coded by VEGF gene. We found relationships between the validated target genes of miR-1 and miR-206 through GeneMania which we extracted from the literature. And we elucidated the proposed structure of these two miRNAs through miR-Mfold web-tool. Conclusion: Our results elucidated a novel regulation pathway in CRC cells and may suggest a potential therapeutic approach for CRC therapy. MiR-1 and miR-206 may help cells go to apoptosis and inhibit the angiogenesis of colorectal cancer cells by down-regulation of MCT4 and VEGF proteins in tumor tissues.

Download Full-text